560 related articles for article (PubMed ID: 3134901)
1. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
Bachmann F
Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
[TBL] [Abstract][Full Text] [Related]
2. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
3. [New thrombolytic agents].
Nguyen G; Samama M
Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
[TBL] [Abstract][Full Text] [Related]
4. Fibrin-specific thrombolytic agents.
Collen D
Schweiz Med Wochenschr; 1987 Nov; 117(46):1791-8. PubMed ID: 3122317
[TBL] [Abstract][Full Text] [Related]
5. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
6. Fibrinolytic agents: mechanisms of activity and pharmacology.
Lijnen HR; Collen D
Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D; Lijnen HR
Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
[TBL] [Abstract][Full Text] [Related]
8. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
9. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
Fry ET; Mack DL; Sobel BE
Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
[TBL] [Abstract][Full Text] [Related]
10. Serine-proteases as plasminogen activators in terms of fibrinolysis.
Flemmig M; Melzig MF
J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
[TBL] [Abstract][Full Text] [Related]
11. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
12. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
14. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
Paloma MJ; Páramo JA; Rocha E
Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
[TBL] [Abstract][Full Text] [Related]
15. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
Wojta J; Binder BR; Huber K; Hoover RL
Thromb Haemost; 1989 Apr; 61(2):289-93. PubMed ID: 2501899
[TBL] [Abstract][Full Text] [Related]
17. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
18. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
[No Abstract] [Full Text] [Related]
19. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
20. Fibrin-specific thrombolytic agents.
Collen D
Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]